Payment & Shipping Terms:
|Name:||L-5-Methyltetrahydrofolate||Cas:||31690 09 2|
|Standard:||Enterprise Standard||Use:||Dietary Supplement|
5 methyltetrahydrofolate calcium,
l methylfolate calcium
5 MTHF Folic Acid Derivatives L 5 Methyltetrahydrofolate CAS 31690 09 2
L-methylfolate is the biologically active form of vitamin B9. That means it is the form the human body can actually use in circulation.
It goes by several other common names including:
L-Methylfolate calcium (refers to the calcium salt molecule it is attached to);
5-MTHF and L-5-MTHF (in this article 5-MTHF refers to L-5-MTHF);
(6S)-5-methyltetrahydrofolate and Quatrefolic.
It is the primary biologically active form of folate used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine. It is also the form found in circulation and transported across membranes into tissues and across the blood-brain barrier. In the cell, L-methylfolate is used in the methylation of homocysteine to form methionine and tetrahydrofolate (THF). THF is the immediate acceptor of one carbon units for the synthesis of thymidine-DNA, purines (RNA and DNA) and methionine. The un-methylated form, folic acid (vitamin B9), is a synthetic form of folate, and must undergo enzymatic reduction by methylenetetrahydrofolate reductase (MTHFR) to become biologically active.
It is synthesized in the absorptive cells of the small intestine from polyglutamylated dietary folate. It is a methylated derivative of tetrahydrofolate. Levomefolic acid is generated by MTHFR from 5,10-methylenetetrahydrofolate (MTHF) and used to recycle homocysteine back to methionine by methionine synthase (MS).
L-methylfolate is water-soluble and primarily excreted via the kidneys. In a study of 21 subjects with coronary artery disease, peak plasma levels were reached in one to three hours following oral or parenteral administration. Peak concentrations were found to be more than seven times higher than folic acid (129 ng/ml vs. 14.1 ng/ml).
|Appearance||White or yellowish powder||Conforms|
|Identification||The retention time of the principle peak in HPLC conforms with that of the stanard||Conforms|
|Residual solvents(Ethanol)||≤5000ppm||Not detected|
|Assay (on dry basis)||97.0%~103.0%||99.1%|
1) Major depressive disorder
Preliminary research suggests that levomefolic acid (L-methylfolate) taken with a first-line antidepressant may provide an adjunctive antidepressant effect for individuals who do not respond or have only a partial therapeutic response to SSRI or SNRI medication.
2) Diabetic neuropathy
Early studies show L-Methylfolate supplementation may be beneficial in treating severe depression and diabetic neuropathy.
3) supplementing L-Methylfolate is the clear alternative while pregnant
Supplementing with L-Methylfolate while pregnant is the clear alternative for those who suspect an issue with metabolising folic acid.
4) Cardiovascular disease and cancer
L-methylfolate has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers. It bypasses several metabolic steps in the body and better binds thymidylate synthase with FdUMP, a metabolite of the drug fluorouracil.